613. Acute Myeloid Leukemia: Clinical and Epidemiological: Practice-changing studies
Sergej Konoplev, Guilin Tang, Xiaoqiong Wang, et al.
According to the study results, it is recommended that all myeloid neoplasms with KMT2A (MLL) rearrangement be classified as AML, regardless of the number of blasts.
Sangeetha Venugopal, Tapan M. Kadia, Farhad Ravandi, et al.
In patients with ts-AML and previous exposure to HMA, HMA + Ven resulted in significantly higher ORR rates and improved OS compared to IC / LIC, especially in patients with a non-adverse risk karyotype and in patients 60 years of age or more. Thus, instead of chemotherapy-based therapies, HMA + Ven should be preferred in patients with ts-AML and previous exposure to HMA. The study results also confirm the very poor outcome results of ts-AML. This is a poor risk subgroup of AML where new, effective therapies are needed.
Andrew Matthews, Alexander E. Perl, Selina M. Luger, et al.
The study found no statistically significant difference in overall survival between induction with CPX-351 and ven/aza.
Ga-Young Song, Taehyung Kim, Seo-Yeon Ahn, et al.
The presence of STM is an independent unfavorable prognostic factor for AML. This can be overcome through allogeneic HCT.
Talha Badar, Mark R. Litzow, Rory M. Shallis, et al.
Despite generally poor results, in a subgroup of these patients, alloHCT appears to improve long-term survival.
Musa Yilmaz, Hagop Kantarjian, Nicholas J. Short, et al.
First and second-generation FLT3i-based doublet therapies generated comparable response rates. The survival rate in older adults with newly diagnosed FLT3 mutated AML was 9-16 months. The triplet combination was able to significantly improve the CR / CRi rates, the FLT3-PCR and MFC-MRD rates, and also the overall survival. The early mortality in this retrospective analysis was not increased. Prospective validation of triplet therapy in older and/or unfit AML patients would be desirable.